Skip to main content
Ocumension Therapeutics logo

Ocumension Therapeutics — Investor Relations & Filings

Ticker · 1477 ISIN · KYG674111011 LEI · 5493000USURI3SIL4Z85 HKEX Manufacturing
Open in API
Filings indexed 460 across all filing types
Latest filing 2026-06-04 Regulatory Filings
Country KY Cayman Islands
Listing HKEX 1477

About Ocumension Therapeutics

http://www.ocumension.com

Ocumension Therapeutics is an ophthalmic pharmaceutical platform company dedicated to the research, development, and commercialization of first-in-class or best-in-class therapeutics. The company focuses on providing comprehensive treatment solutions for Chinese patients suffering from ocular diseases. Ocumension has established a complete ophthalmic drug product line, currently holding 20 drug assets covering both anterior and posterior segments of the eye. Its portfolio addresses major conditions such as chronic non-infectious uveitis, infective and allergic conjunctivitis, and diabetic macular edema. The company employs a strategy combining continuous scientific innovation, independent R&D, and strategic alliances to sustain the supply of innovative products across the ophthalmology field.

Recent filings

Filing Released Lang Actions
Monthly Return of Equity Issuer on Movements in Securities for the Month ended 31 May 2026
Regulatory Filings Classification · 88% confidence The document is a mandatory monthly return filed by a Hong Kong listed issuer (Ocumension Therapeutics) under HKEX Listing Rules Chapter 19B, detailing movements in share capital, issued shares, treasury shares, share option schemes, and confirmations. It is a recurring regulatory compliance submission rather than a financial report, earnings release, or any corporate action announcement like M&A or director dealings. Therefore, it falls under the general Regulatory Filings category (RNS) as a listing-rule compliance document.
2026-06-04 English
VOLUNTARY ANNOUNCEMENT FIRST PATIENT ENROLLMENT COMPLETED IN THE PHASE III CLINICAL TRIAL OF OT-802
Regulatory Filings Classification · 85% confidence The document is a voluntary announcement issued on the Hong Kong Exchange regarding the first patient enrollment in a Phase III clinical trial. It is not an annual or interim financial report, earnings release, director change, share issue, dividend notice, corporate presentation, or any other specific filing type. It is a miscellaneous business/regulatory update. According to the fallback category definition, this should be classified as a general Regulatory Filing (RNS).
2026-05-28 English
GRANTS OF OPTIONS AND AWARDS
Share Issue/Capital Change Classification · 78% confidence The document is a public regulatory announcement under the Hong Kong Listing Rules disclosing the details of grants of share options and share awards under the Company’s 2021 Share Option Scheme and 2021 Share Award Scheme. It is not a financial report, earnings release, management discussion, or remuneration proxy statement, nor is it an insider personal trade (DIRS) or share buy-back (POS). It represents a capital change – the grant of rights to subscribe for new shares – and thus best fits our Share Issue/Capital Change category (Code: SHA).
2026-05-12 English
Monthly Return of Equity Issuer on Movements in Securities for the Month ended 30 April 2026
Regulatory Filings Classification · 95% confidence The document is a detailed monthly return report for an equity issuer listed on the Hong Kong Stock Exchange, specifically under Chapter 19B of the Exchange Listing Rules. It provides comprehensive data on movements in authorised share capital, issued shares, treasury shares, share options, and confirmations related to compliance with listing rules. The document is not a financial report like an annual or interim report, nor is it an earnings release or a management discussion. It is a regulatory filing that reports on share capital movements and compliance confirmations as required by the exchange. The document length is substantial (12,690 characters), and it contains detailed data rather than just an announcement or certification. Therefore, it fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous compliance and regulatory reports that do not fit other specific categories.
2026-05-06 English
Notification Letter to Non-registered Shareholders and Reply Form - Arrangement of Electronic Dissemination of Corporate Communications
Regulatory Filings Classification · 15% confidence The document is a reminder letter to non-registered shareholders about the Company’s arrangement for electronic dissemination of corporate communications and includes a reply form to elect printed or electronic copies. It does not itself contain an annual or interim report, proxy solicitation materials for a specific meeting, or any voting results, nor is it a report announcement of a financial document. It is essentially a general regulatory notice to shareholders under Listing Rules, which falls into the fallback “Regulatory Filings” category.
2026-04-28 English
Notification Letter to Registered Shareholders and Reply Form - Arrangement of Electronic Dissemination of Corporate Communications
Regulatory Filings Classification · 85% confidence The document is a reminder letter to shareholders about the electronic dissemination arrangement for corporate communications and includes a reply form. It is not reporting financial results, it is not an annual or interim report, nor a proxy solicitation or voting announcement. It is an operational/regulatory notification without substantive financial content, so it falls into the general “Regulatory Filings” fallback category.
2026-04-28 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.